Comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute sinusitis in adults (Q33420344)

26 July 2017

title

Comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute sinusitis in adults (English)

1 reference

26 July 2017

1 reference

J Adelglass

1 reference

26 July 2017

C A DeAbate

1 reference

26 July 2017

P McElvaine

1 reference

26 July 2017

C L Fowler

1 reference

26 July 2017

J LoCocco

1 reference

26 July 2017

T Campbell

1 reference

26 July 2017

publication date

1 March 1999

1 reference

Otolaryngology—Head and Neck Surgery

26 July 2017

published in

1 reference

26 July 2017

volume

120

1 reference

26 July 2017

1 reference

26 July 2017

page(s)

320-327

1 reference

Does this patient have sinusitis? Diagnosing acute sinusitis by history and physical examination

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0194-5998%2899%2970269-X

Acute and chronic sinusitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0194-5998%2899%2970269-X

The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0194-5998%2899%2970269-X

Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0194-5998%2899%2970269-X

In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0194-5998%2899%2970269-X

Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0194-5998%2899%2970269-X

Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0194-5998%2899%2970269-X

Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0194-5998%2899%2970269-X

Levofloxacin in vitro activity against bacteremic isolates of Streptococcus pneumoniae. Franklin County Pneumonia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0194-5998%2899%2970269-X

7 January 2021

The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci

1 reference

https://api.crossref.org/works/10.1016%2FS0194-5998%2899%2970269-X

7 January 2021

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses

1 reference

https://api.crossref.org/works/10.1016%2FS0194-5998%2899%2970269-X

7 January 2021

The Efficacy and Safety of Once-Daily Ceftibuten Compared with Co-amoxiclav in the Treatment of Acute Bacterial Sinusitis

1 reference

https://api.crossref.org/works/10.1016%2FS0194-5998%2899%2970269-X

7 January 2021

A double-blind comparison of ciprofloxacin and amoxycillin/clavulanic acid in the treatment of chronic sinusitis

1 reference

https://api.crossref.org/works/10.1016%2FS0194-5998%2899%2970269-X

7 January 2021

10.1016/S0194-5998(99)70269-X

Identifiers

DOI

1 reference

26 July 2017

1 reference